Influence of Preparation Methods on Physicochemical and Pharmacokinetic Properties of Co-amorphous Formulations: The Case of Co-amorphous Atorvastatin: Naringin

被引:32
|
作者
Nair, Athira [1 ]
Varma, Raghava [1 ]
Gourishetti, Karthik [2 ]
Bhat, Krishnamurthy [1 ]
Dengale, Swapnil [1 ]
机构
[1] Manipal Acad Higher Educ, Manipal Coll Pharmaceut Sci, Dept Pharmaceut Qual Assurance, Manipal 576104, Karnataka, India
[2] Manipal Acad Higher Educ, Manipal Coll Pharmaceut Sci, Dept Pharmacol, Manipal 576104, India
关键词
Co-amorphous; Atorvastatin; Naringin; Ball milling; Solvent evaporation; Quench cooling; SOLID-STATE CHARACTERIZATION; IMPROVED PHYSICAL STABILITY; WATER-SOLUBLE DRUGS; DISSOLUTION RATE; COAMORPHOUS ATORVASTATIN; ENHANCED BIOAVAILABILITY; ENTHALPIC RELAXATION; BINARY-SYSTEMS; DOSAGE FORMS; AMINO-ACIDS;
D O I
10.1007/s12247-019-09381-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose The goal of the study was to investigate the influence of processing methods on the physicochemical and pharmacokinetic properties of co-amorphous materials. Methods Co-amorphous formulations of atorvastatin (ATV) and naringin (NRG) in the molar ratio 1:1 were prepared by quench cooling (ANQC), solvent evaporation (ANSE), and ball milling (ANBM) and characterized by differential scanning calorimetry (DSC), powder X-ray diffractometry (XRPD), and Fourier transform infrared spectroscopy (FTIR). Further, the performance of prepared co-amorphous formulations was evaluated in vitro and in vivo. Results All processing methods yielded homogeneous co-amorphous formulation, which was confirmed by single glass transition (Tg) event and diffuse halo in DSC and XRPD, respectively. Irrespective of processing method employed, all co-amorphous formulations were found stable at 30 degrees C for 90 days in dry conditions (under vacuum). Significant improvement in the solubility of ATV was observed in ANQC and ANSE co-amorphous formulations, highest being 56-fold for the later. ATV from ANSE formulation showed highest drug release (97%), while surprisingly ANQC showed significantly lower ATV release as compared to the physical mixture. Amongst three preparation methods, solubility advantage of ANSE could translate into efficacious pharmacokinetic parameters, where the improvement in ATV exposure (AUC 0-t) and plasma concentration (Cmax) were found 4.5-fold and 7-fold, respectively, as compared to the physical mixture. Conclusion It was concluded that the preparation methods of co-amorphous formulations have a profound effect on physical properties like stability, physicochemical properties like solubility, dissolution rate, and pharmacokinetic properties like AUC and Cmax.
引用
收藏
页码:365 / 379
页数:15
相关论文
共 50 条
  • [1] Influence of Preparation Methods on Physicochemical and Pharmacokinetic Properties of Co-amorphous Formulations: The Case of Co-amorphous Atorvastatin: Naringin
    Athira Nair
    Raghava Varma
    Karthik Gourishetti
    Krishnamurthy Bhat
    Swapnil Dengale
    Journal of Pharmaceutical Innovation, 2020, 15 : 365 - 379
  • [2] Application of Co-Amorphous Technology for Improving the Physicochemical Properties of Amorphous Formulations
    Mizoguchi, Ryo
    Waraya, Haruka
    Hirakura, Yutaka
    MOLECULAR PHARMACEUTICS, 2019, 16 (05) : 2142 - 2152
  • [3] Raloxifene HCl - Naringin co-amorphous system: Preparation, characterization and pharmacokinetic studies
    Srinivas, Navya Sree Kola
    Yarlagadda, Dani Lakshman
    Bheemishetty, Brahmam
    Lewis, Shaila
    Dengale, Swapnil Jayant
    Bhat, Krishnamurthy
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2025, 209
  • [4] Organic acids as co-formers for co-amorphous systems - Influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems
    Wu, Wenqi
    Ueda, Hiroshi
    Lobmann, Korbinian
    Rades, Thomas
    Grohganz, Holger
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2018, 131 : 25 - 32
  • [5] Physical Properties for Novel Cilostazol Co-amorphous; Effect of Preparation Method and Molar Ratio on the Co-amorphous
    Takayama, Tomoki
    Kaneko, Shun
    Palanisamy, Vasanthi
    Ono, Makoto
    Titapiwatanakun, Varin
    Higashi, Kenjirou
    Fukami, Toshiro
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2025, 73 (04) : 318 - 326
  • [6] Considerations for the selection of co-formers in the preparation of co-amorphous formulations
    Yarlagadda, Dani Lakshman
    Vullendula, Sai Krishna Anand
    Nair, Athira R.
    Sree, K. S. Navya
    Dengale, Swapnil J.
    Bhat, Krishnamurthy
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 602
  • [7] Rational excipient selection for co-amorphous formulations
    Korhonen, Ossi
    Pajula, Katja
    Laitinen, Riikka
    EXPERT OPINION ON DRUG DELIVERY, 2017, 14 (04) : 551 - 569
  • [8] Recent advances in co-amorphous drug formulations
    Dengale, Swapnil Jayant
    Grohganz, Holger
    Rades, Thomas
    Lobmann, Korbinian
    ADVANCED DRUG DELIVERY REVIEWS, 2016, 100 : 116 - 125
  • [9] Transformations between Co-Amorphous and Co-Crystal Systems and Their Influence on the Formation and Physical Stability of Co-Amorphous Systems
    Wu, Wenqi
    Wang, Yixuan
    Lobmann, Korbinian
    Grohganz, Holger
    Rades, Thomas
    MOLECULAR PHARMACEUTICS, 2019, 16 (03) : 1294 - 1304
  • [10] Characterization of Amorphous and Co-Amorphous Simvastatin Formulations Prepared by Spray Drying
    Craye, Goedele
    Lobmann, Korbinian
    Grohganz, Holger
    Rades, Thomas
    Laitinen, Riikka
    MOLECULES, 2015, 20 (12) : 21532 - 21548